

№462, 17-yanvar, 2022 y.

COVID-19 ga qarshi vaksinalarning
ishlanmalari bo'yicha

DAYJEST

O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi











Toshkent-2022

Jahonda pandemiya bilan bog'liq vaziyat

2022 y. 16-yanvar holatiga ko'ra

Umumiy zararlanganlar soni	-	326 674 090	(+ 2 427 109)
Sog'ayganlar soni	-	266 411 376	(+ 1 089 446)
Vafot etganlar soni	-	5 553 522	(+ 5 778)

Mamlakatlar bo'yicha bemorlar soni

	AQSh	-	66 664 283	(+ 404 141)
	Hindiston	-	37 122 164	(+ 271 202)
	Braziliya	-	22 975 723	(+ 48 520)
	Buyuk Britaniya	-	15 147 120	(+ 81 713)
	Fransiya	-	13 894 255	(+ 324 580)
	Rossiya	-	10 774 304	(+ 27 179)
	Turkiya	-	10 403 064	(+ 63 967)
	Italiya	-	8 549 450	(+ 180 426)
	Ispaniya	-	8 093 036	(+ 162 508)
	O'zbekiston	-	205 085	(+ 912)

Manba: <https://www.worldometers.info/coronavirus/>



O'zbekistonda COVID-19 qarshi vaksinatsiya bo'yicha hisobot

2022 y. 15-yanvar holatiga ko'ra

Hududlar	Jami emlanganlar soni	Bir kunda emlanganlar soni
Qoraqalpog'iston Respublikasi	2 062 148	3 362
Andijon viloyati	3 876 491	9 566
Buxoro viloyati	2 262 148	9 074
Jizzax viloyati	1 423 749	2 094
Qashqadaryo viloyati	3 086 009	13 808
Navoiy viloyati	1 315 907	1 958
Namangan viloyati	3 811 757	8 033
Samarqand viloyati	4 921 788	16 586
Surxondaryo viloyati	3 241 700	8 994
Sirdaryo viloyati	883 212	2 819
Toshkent viloyati	3 831 820	14 028
Farg'ona viloyati	4 427 288	10 784
Xorazm viloyati	2 443 092	9 371
Toshkent sh.	3 070 676	23 585
Jami	40 657 785	134 062

Manba: SSV matbuot kotibi // <https://t.me/ssvmatbuotkotibi>



JSST tomonidan baholash jarayonida COVID-19 ga qarshi vaksinlarning holati

2022 y. 15-yanvar holatiga ko'ra


№	Ishlab chiqaruvchi	Vaksina nomi	Platforma	Arizalarni qabul qilish	Uchrashuv o'tkazish	Ma'lumotnomani ko'rib chiqish uchun qabul qilish	Baholash holati	Kutilayotgan chiqish sanasi
1	Pfizer	BNT162b2/COMIRNATY	mRNA	+	+	+	Yakunlangan	Tasdiqlangan 31.12.2020
2	AstraZeneca/University of Oxford	AZD1222	Recombinant replication defective chimpanzee adenovirus expressing surface glycoprotein SARS-CoV-2	+	+	+	Yakunlangan	Tasdiqlangan 15.02.2021
3	Janssen	Ad26.COV2.S	Recombinant vector vaccine against adenovirus type 26 (Ad26), incapable of replication, encoding Spike (S) protein (SARS-CoV-2)	+	+	+	Yakunlangan	Tasdiqlangan 12.03.2021
4	SK BIOscience - AstraZeneca/University of Oxford	AZD1222	Recombinant adenoviral vector ChAdOx1 encoding the Spike SARS-CoV-2 protein antigen	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
5	Serum institute of India	Covishield	mRNA-based vaccine encapsulated in lipid nanoparticles	+	+	+	Yakunlangan	Tasdiqlangan 16.04.2021
6	Moderna	mRNA-1273	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 30.04.2021
7	Sinopharm / BIBP	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	Inactivated, produced in Vero cells	+	+	+	Yakunlangan	Tasdiqlangan 07.05.2021
8	Sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	Protein subunit virus-like particle vaccine	+	+	+	Yakunlangan	Tasdiqlangan 01.06.2021
9	Novavax	NVX-CoV2373, Covovax, Nuvaxovid		+	+	+	Yakunlangan	Tasdiqlangan 17.12.2021

Manba:

Status of COVID-19 Vaccines within WHO EUL // https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Oct2021.pdf

Vaksinani tasdiqlagan va undan foydalanilayotgan mamlakatlar soni

2022 y. 15-yanvar holatiga ko'ra



Manbalar:

*Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

COVID-19 Vaccine Market Dashboard //

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>


**Tracking Coronavirus Vaccinations Around the World //

<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>

Mamlakatlar va kontinentlar kesimida COVID-19 ga qarshi emlanganlar soni

2022 y. 15-yanvar holatiga ko'ra

№	Davlatlar	Emlanganlar soni		Aholining umumiy sonida emlanganlarning ulushi	
		100 ta kishiga	Jami	Bitta doza bilan emlangan	To'liq emlangan
	Dunyo	125	9 624 532 826	61 %	52 %
1	BAA	235	22 985 689	99 %	94 %
2	Bruney	213	922 950	94 %	93 %
3	Portugaliya	197	20 247 208	93 %	89 %
4	Kuba	284	32 161 357	93 %	86 %
5	Chili	240	45 533 794	92 %	88 %
6	Malta	231	1 159 050	90 %	87 %
7	Xitoy	210	2 928 981 000	90 %	87 %
8	Kambodja	189	31 218 844	87 %	83 %
9	Argentina	183	82 026 588	87 %	75 %
10	Janubiy Koreya	210	108 759 434	86 %	84 %




Manba:
Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>



COVID-19 ga qarshi vaksinalarning narxi

2022 y. 15-yanvar holatiga ko'ra

No	Vaksinaning ishlab chiqaruvchisi	Vaksinalarning narxi (bitta doza uchun)*
1	Pfizer	\$6,75-22,94
2	AstraZeneca/University of Oxford	\$2,19-5
3	Serum institute of India	\$3-13,27
4	Sinopharm	\$144,27 (2 ta doza uchun)
5	Sinovac	\$10,30-29,75
6	Moderna	\$15-37
7	Janssen	\$8,50-10
8	The Gamaleya National Center (Sputnik V)	\$11-19,90



Manba:

* COVID-19 Vaccine Market Dashboard //

[https://www.unicef.org/supply/covid-19-vaccine-market-](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)

[dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard?utm_source=facebook&utm_medium=organic&utm_campaign=coronavirus&fbclid=IwAR101804JupyKfUU1u6osTc-nNVGj7kiYDI8eJtiMUgjEIALGhYO3w0EE)



Olimlar koronavirus infeksiyasining kamayish holatini aniqladilar

Ochiq havoga chiqqandan so'ng koronavirus 20 daqiqa ichida yuqtirish qobiliyatining 90 foizini yo'qotadi, eng katta yo'qotish esa birinchi besh daqiqa ichida sodir bo'ladi. Bu virus ochiq havoda qanday omon qolishini dunyodagi birinchi modellashtirish bilan tasdiqlangan [2].

Britaniya olimlari tomonidan olib borilgan tadqiqotlar natijalariga ko'ra COVID-19 qisqa masofani bosib o'tishini tasdiqlaydi, ijtimoiy masofa va niqob taqish, ehtimol, infeksiyani oldini olishning eng samarali usuli hisoblanadi. Havoni almashtirish amalga oshirilga taqdirda, kamroq ta'sir qilishi mumkin.

“Insonlar yomon havo aylanadigan binolarda infeksiya bir necha metr yoki xona bo'ylab havo tomchi orqali yuqishi mumkin deb o'ylashadi. Men bunday deb uylamayman, ammo menimcha, infeksiyaning eng katta xavfi kasallangan shaxslarga yaqin bo'lganingizda yuqish tezligi yuqori”, dedi Bristol universitetining Aerozol tadqiqot markazi direktori va tadqiqotning yetakchi muallifi professor Jonatan Rid.

Virus zarralari o'pkani nisbatan nam va karbonat angidridga boy qoldirishi sababli ular tezda suvni yo'qotadi va quriydi. Bu omillarning ikkalasi ham virus insonga zarar yetkazish qobiliyatini kamaytiradi, ammo zarrachalarning qurish tezligi atrof-muhitning nisbiy namligiga qarab o'zgaradi. Ko'plab idoralardagi nisbatan quruq havo sababli virus besh soniya ichida



o'z samaradorligining yarmini yo'qotgan, bu ko'rsatkich 50% dan past bo'lgan. 90% namlikda (taxminan dushga teng) infeksiyaning pasayishi asta-sekin sodir bo'lib, 5 daqiqadan so'ng zarrachalarning 52% yuqumli bo'lib qoldi va 20 daqiqadan so'ng taxminan 10% gacha pasaydi, shundan so'ng ular o'rtasida hech qanday farq qolmagan.

Biroq, virusning tarqalishi yuqori haroratlarda past bo'ladi degan mashhur e'tiqoddan farqli o'laroq, havo harorati virusli infeksiyaga ta'sir qilmaydi. Bu odamlar ijtimoiy jihatdan uzoqlasha olmaydigan holatlarda niqob kiyish muhimligini ta'kidlaydi, deya qo'shimcha qildi professor [3].

AstraZeneca ma'lum qilishicha, Vaxzevria COVID-19 vaktsinasining uchinchi dozasi virusning Omicron shtamidan himoya qiladi

Shvetsiya-Britaniya farmatsevtika kompaniyasi AstraZeneca ma'lum qilishicha, Vaxzevria COVID-19 vaktsinasining uchinchi dozasi virusning Omicron shtamidan himoya qiladi. Farmatsevtika kompaniyasi sinov jarayonlarining dastlabki ma'lumotlariga tayanadi, deb yozadi Reuters axborot agentligi [4].

Tadqiqotchilar sinovlar davomida Vaxzevria vaktsinasining uchinchi kuchaytiruvchi dozasi Omicron va boshqa variantlarga qarshi antitanalarning ko'payishiga olib kelganligini aniqladilar.



“Vaxzevria yoki mRNK preparati (Pfizer yoki Moderna) bilan avval emlangan insonlarda antitanalarning ko'payishi kuzatildi”, — deyiladi kompaniya xabarida.

Kompaniyaning ta'kidlashicha, bu natijalar butun dunyo bo'ylab tartibga soluvchi organlarga taqdim etiladi, ular o'z vaktsinalaridan asosiy vaktsina dozasi uchun foydalanishlari mumkin. AstraZeneca shuningdek, bugungi nomaxsus bayonot kompaniyaning ikki kursli mRNK asosidagi vaktsina yoki Vaxzevria dan keyin kuchaytiruvchi vosita sifatida Vaksevriyaning himoya samaradorligi haqidagi birinchi bayonoti ekanligini ta'kidlaydi [5].

Daniya hukumati SARS-CoV-2 ga qarshi to'rtinchi dozani taklif qilmoqda

Daniya hukumati mamlakat aholisiga SARS-CoV-2 koronavirusga qarshi vaksinaning to'rtinchi dozasi olish imkoniyatini taqdim etmoqda. Sog'liqni saqlash vaziri Magnus Xeynikening so'zlariga ko'ra, kuchaytiruvchi vakcina infeksiyaga eng zaif odamlarga taklif etiladi. Sog'liqni saqlash organlari yaqin kunlarda ular bilan bog'lanadi [6].

Shu bilan birga, rasmiy Kopengagen sog'liqni saqlash pasporti deb atalmish amal qilish muddatini qisqartirdi. Endilikda, COVID-19 ga qarshi ikkita emlangan qirolik aholisi uchun ushbu hujjat vaksinaning ikkinchi dozasi keyin yetti oy o'rniga besh oy davomida amal qiladi. Rezentlarning 54,6 foizi tomonidan amalga oshirilgan uchinchi inyeksiya pasporti cheksiz amal qilish muddatini bildiradi.

Jurnalistlar yozganidek, COVID-19 ga qarshi emlash huquqi immuniteti keskin zaiflashgan, shuningdek, onkologik va boshqa jiddiy kasalliklarga chalingan kishilarga beriladi [7].



© Ólafur Steinar Rye Gestsson/Ritzau Scanpix/AP/Getty Images

Mutaxassislarning fikriga ko'ra, Turkiyaning Turkovac vaktsinasi Sinovac singari samarali

Mutaxassislarning ta'kidlashicha, Turkiyada ishlab chiqilgan mahalliy inaktivlangan Turkovac vaktsinasi, o'tkazilgan III bosqich sinov natijalariga ko'ra, Xitoyning Sinovac kompaniyasi vaktsinasi kabi samarali ekanligini ko'rsatdi [8].



Turkiya milliy vaktsinadan 2021-yil dekabr oyi oxirida mahalliy hukumat favqulodda vaziyatlarda foydalanishga ruxsat berganidan so'ng foydalanishni boshladi, deb yozadi Hurriyet. Mamlakat o'tgan yanvar oyida Sinovac vaktsinasi bilan ommaviy emlash dasturini boshlagan edi, keyinroq Pfizer/BioNTech vaktsinalari kiritildi.

“Bu ikki vaktsina bir xil yon ta'sirga ega. Turkovac Sinovacning CoronaVac vaktsinasi singari xavfsizdir”, dedi Hacettepe universiteti Vaktsina instituti professori Mine Durusu Tanriover Anqaradagi matbuot anjumanida. Tanriover 18 yoshdan 55 yoshgacha bo'lgan ko'ngillilarga COVID-19 ga qarshi qo'llangan Turkovacning ikki dozasi va CoronaVacning ikki dozasi samaradorligini sinab ko'rishga qaratilgan tadqiqot o'tkazilganini ta'kidladi.

Ko'ngillilarning yarmi mahalliy Turkovac vaktsinasini, qolganlari esa CoronaVac vaktsinasini 28 kunlik farq bilan qabul qilishdi, dedi u.

“Tadqiqot 2021-yilning 22-iyunidan 27-dekabriga qadar sinovlarda qatnashgan ko'ngillilarning natijalarini o'z ichiga olgan. Ikkala tadqiqot vaktsinalari ham jami 2444 kishiga yuborilgan. Protokollarga rioya qilmaganlarni hisobga olmaganda, 1182 nafar ko'ngillida samaradorlik sinovlari o'tkazildi”, — deya qo'shimcha qildi u.

Tanriover, Turkovac vaktsinasi uchun kuzatuv davri sinovning uchinchi bosqichida 108 kunni tashkil etgan bo'lsa, Sinovac vaktsinasi uchun 43 kunni tashkil etdi.

Samaradorlik testlarida qatnashgan 108 nafar ko'ngillilar orasida 69 nafari COVID-19 uchun ijobiy sinovdan o'tgan. “Ulardan 23 nafari Turkovac vaktsinasini qabul qilishgan. Ijobiy davolash darajasi Turkovac uchun 4,55% va CoronaVac uchun 8,96% ni tashkil etdi. Natijalarga asoslanib, mahalliy vaktsina CoronaVacga qaraganda 49 foizga samaraliroq”, — deya xulosa qildi ekspert [9].



COVID
19
Coronavirus
Vaccine

Manbalar

1. Reported Cases and Deaths by Country, Territory, or Conveyance // <https://www.worldometers.info/coronavirus/> (16.01.2022)
2. Approved or Authorized Vaccines // <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html> (16.01.2022)
3. COVID-19 Vaccine Market Dashboard // <https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> (16.01.2022)
4. Tracking Coronavirus Vaccinations Around the World // <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html> (16.01.2022)
5. Covid loses 90% of ability to infect within 20 minutes in air – study // <https://www.theguardian.com/world/2022/jan/11/covid-loses-90-of-ability-to-infect-within-five-minutes-in-air-study> (16.01.2022)
6. Ученые выяснили условие уменьшения заразности коронавируса // <https://www.online.ua/> (16.01.2022)
7. AstraZeneca says early trial data indicates third dose helps against Omicron // <https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-higher-antibody-response-against-omicron-with-booster-dose-2022-01-13/?taid=61e00e6adf9b5d00016f8ccb> (16.01.2022)
8. Третья доза нашей вакцины защищает против штамма "Омикрон" – AstraZeneca // <https://coronavirus.tsn.ua/ru/tretya-doza-nashey-vakciny-zaschischaet-protiv-shtama-omikron-astrazeneca-1952608.html> (16.01.2022)
9. Власти Дании предлагают уже четвертую прививку от SARS-CoV-2 // <https://www.dw.com/ru/v-danii-predlagajut-uzhe-chetvertuju-privivku-ot-sars-cov-2/a-60405407> (16.01.2022)
10. Жителям Дании начнут предлагать сделать четвертую прививку от COVID-19 // <https://regnum.ru/news/society/3475430.html> (16.01.2022)
11. Local jab Turkovac as effective as Sinovac: Experts // <https://www.hurriyetdailynews.com/local-jab-turkovac-as-effective-as-sinovac-experts-170727> (16.01.2022)
12. Эксперты: Турецкая вакцина Turkovac так же эффективна, как и Sinovac // <https://mk-turkey.ru/life/2022/01/13/kak-i-sinovac.html> (16.01.2022)



O'zbekiston Respublikasi Innovatsion rivojlanish vazirligi huzuridagi
Ilmiy-texnik axborot markazi

Toshkent-2022